Two antibacterial and PPARα/γ-agonistic unsaturated keto fatty acids from a coral-associated actinomycete of the genus Micrococcus

  1. Amit Raj Sharma1,
  2. Enjuro Harunari1,
  3. Naoya Oku1ORCID Logo,
  4. Nobuyasu Matsuura2,
  5. Agus Trianto3 and
  6. Yasuhiro Igarashi1

1Biotechnology Research Center and Department of Biotechnology, Toyama Prefectural University, 5180 Kurokawa, Imizu, Toyama 939-0398, Japan
2Okayama University of Science, 1-1 Ridaicho, Okayama 700-0005, Japan
3Faculty of Fisheries and Marine Sciences, Diponegoro University, Tembalang Campus, St. Prof. Soedarto SH., Semarang 50275, Central Java, Indonesia

  1. Corresponding author email

Associate Editor: S. Bräse
Beilstein J. Org. Chem. 2020, 16, 297–304. doi:10.3762/bjoc.16.29
Received 01 Nov 2019, Accepted 14 Feb 2020, Published 02 Mar 2020

Abstract

A pair of geometrically isomeric unsaturated keto fatty acids, (6E,8Z)- and (6E,8E)-5-oxo-6,8-tetradecadienoic acids (1 and 2), were isolated from the culture broth of an actinomycete of the genus Micrococcus, which was associated with a stony coral, Catalaphyllia sp. Their chemical structures were elucidated by spectroscopic analysis including NMR and MS, with special assistance of spin system simulation studies for the assignment of an E geometry at C8 in 2. As metabolites of microbes, compounds 1 and 2 are unprecedented in terms of bearing a 2,4-dienone system. Both 1 and 2 showed antibacterial activity against the plant pathogen Rhizobium radiobacter and the fish pathogen Tenacibaculum maritimum, with a contrasting preference that 1 is more effective to the former strain while 2 is so to the latter. In addition, compounds 1 and 2 displayed agonistic activity against peroxisome proliferator-activated receptors (PPARs) with an isoform specificity towards PPARα and PPARγ.

Keywords: antibacterial; coral; keto fatty acid; Micrococcus; PPAR

Introduction

Marine actinobacteria are considered as a potential source for novel natural products with high structural diversity, unique biological activity, and molecular modes of action beneficial to drug development [1-3]. Actinobacteria in marine environments are mostly found in association with higher organisms, such as fish, sponges, corals, molluscs, ascidians, seaweeds, and mangroves, and have kept attracting attention due to their ability to produce various bioactive compounds [2,4]. Among the isolation sources for marine actinobacteria, substantial amounts of studies were devoted to sponges from which a wide range of actinobacterial species were found to produce intriguing natural products [5]. Corals, another large group of marine invertebrates, also harbor diverse symbiotic or associating microorganisms [6]. However, only a handful of natural products such, as strepchloritides [7], nahuoic acids B–E [8], and pteridic acids C–G [9], were obtained from actinobacteria associated with soft corals. There is no report indeed on natural products from actinobacteria residing in stony corals.

Actinomycetes of the genus Micrococcus are Gram-positive, aerobic, and nonmotile cocci. Unlike the majority of actinomycetes, they typically form tetrad clusters but not hyphae [10]. Micrococcus is ubiquitous in distribution and, similar to other actinomycetes, marine Micrococcus are commonly associated with marine invertebrates, such as sponges and corals [4,11,12]. Distinct classes of natural products have been isolated from sponge-associated Micrococcus, including glycosylated glycerolipid [13,14], cyclic peptide [15], xanthone glycoside [16], and halogenated diphenyl ether [14]. Until now, however, no natural products are known from coral-associated Micrococcus.

As a part of our ongoing screening program to discover new natural products from coral-associated bacteria, we have recently reported a catecholate siderophore, labrenzbactin, from an alphaproteobacterium Labrenzia [17] and an unsaturated fatty acid with unique methylation pattern from a gammaproteobacterium Microbulbifer [18]. Herein, we report the fermentation, isolation, structure determination, and bioactivity of two new keto fatty acids, (6E,8Z)-5-oxo-6,8-tetradecadienoic acid (1) and its (6E,8E)-isomer 2, from a coral-associated actinomycete Micrococcus sp. C5-9.

Results and Discussion

The producing strain C5-9 was obtained from stony coral Catalaphyllia sp. and identified as a member of the genus Micrococcus by 16S rRNA gene sequence analysis. The HPLC–UV analysis of the fermentation broth of strain C5-9 indicated the presence of metabolites showing UV absorption around 275 nm. A large-scale shaking culture (2.9 L) was carried out in A16 seawater medium at 30 °C for five days to obtain adequate amounts of compounds for structure determination and bioassays. The fermentation broth was extracted with 1-butanol, and the extract was fractionated by solvent/solvent partitioning. Following ODS column chromatography and isocratic reversed-phase preparative HPLC, 1 (3.7 mg) and 2 (2.4 mg) were isolated (Figure 1).

[1860-5397-16-29-1]

Figure 1: Structures of (6E,8Z)- and (6E,8E)-5-oxo-6,8-tetradecadienoic acids (1 and 2).

(6E,8Z)-5-Oxo-6,8-tetradecadienoic acid (1) was obtained as a pale yellow amorphous solid. The molecular formula was determined to be C14H22O3 on the basis of its NMR and HRESIMS-TOF data (m/z 261.1453 [M + Na]+; calcd for C14H22O3Na, 261.1461). The UV spectrum of 1 in methanol exhibited an absorption maximum at 277 nm. The IR absorption bands at 1708 and 2800–3400 cm−1 were suggestive of the carbonyl and hydroxy functionalities. The 13C NMR and DEPT spectra of 1 (Table 1) displayed 14 carbon signals, including one methyl, seven sp3 methylene, four sp2 methine (δC 143.1, 137.5, 129.1, and 126.8), one carboxy (δC 178.2), and one deshielded aldehyde or keto carbon signal (δC 199.8). Four degrees of unsaturation indicated by 13C signals were consistent with the number calculated from the molecular formula, which indicated that 1 had a linear structure. The 1H NMR spectrum showed characteristic resonances for a terminal methyl group at δH 0.89 (3H, t) in the shielded region and for multiple methylene signals, suggesting the presence of an alkyl chain. COSY analysis established three spin systems, one from H2 to H4, a seven-carbon fragment from H6 to H12, and an ethyl fragment H13/H14. These partial structures were joined into one linear structure by HMBC correlations from H3, H4, H6, and H7 to C5, H14 to C12, and H11 to C13. Then, a correlation from H2 and H3 to C1 connected the carboxy group at C2 to complete the structure of 1 (Figure 2). The geometry of the double bonds was E at C6 and Z at C8 based on the coupling constants JH6,H7 = 15.3 Hz and JH8,H9 = 10.8 Hz, respectively.

Table 1: 1H and 13C NMR data for compounds 1 and 2 in CDCl3.

  1 2
position δCa δH mult
(J in Hz)b
HMBCb,c δCa δH mult
(J in Hz)b
HMBCb,c
1 178.2, C     177.7, C    
2 32.9, CH2 2.44, m 1, 3, 4 32.9, CH2 2.42, m 1, 3, 4
3 19.1, CH2 1.97, m 1, 2, 4, 5 19.1, CH2 1.96, quint (7.0) 1, 2, 4, 5
4 39.6, CH2 2.66, t (6.6) 2, 3, 5 39.0, CH2 2.65, t (7.1) 2, 3, 5
5 199.8, C     199.8, C    
6 129.1, CH 6.15, d (15.3) 4, 5, 8 127.6, CH 6.07, d (15.6) 4, 5, 8
7 137.5, CH 7.51, dd
(15.3, 11.7)
5, 6, 8, 9 143.5, CH 7.15, dd
(15.6, 9.5)
5, 8, 9
8 126.8, CH 6.10, dd
(11.7, 10.8)
5, 6, 7, 10 128.7, CH 6.15, dd
(15.6, 9.5)d
6, 7, 10
9 143.1, CH 5.92, dt
(10.8, 7.9)
7, 8, 10, 11 146.2, CH 6.18, dt
(15.6, 6.3)d
7, 10, 11
10 28.3e, CH2 2.31, q (7.5) 8, 9, 11, 12 33.1, CH2 2.18, dt
(6.3, 7.2)
8, 9, 11, 12
11 29.0e, CH2 1.43, quint (7.1) 9, 10, 12, 13 28.3, CH2 1.43, quint (7.2) 10, 12, 13
12 31.4, CH2 1.32f, m 10, 11, 13 31.4, CH2 1.29f, m 11, 13
13 22.5, CH2 1.30f, m 12, 14 22.4, CH2 1.31f, m 12
14 14.0, CH3 0.89, t (6.8) 12, 13 14.0, CH3 0.89, t (6.9) 12, 13

aRecorded at 125 MHz (reference δC 77.0). bRecorded at 500 MHz (reference δH 7.26). cHMBC correlations are from proton(s) stated to the indicated carbon atom. dDetermined by NMR simulations. eAssignment interchangeable. fOverlapping signals.

[1860-5397-16-29-2]

Figure 2: COSY and key HMBC correlations for 1 and 2.

The molecular formula of 2 was also determined to be C14H22O3 on the basis of its NMR and HRESIMS-TOF data (m/z 261.1458 [M + Na]+; calcd for C14H22O3Na, 261.1461). The 1H and 13C NMR spectra of 2 displayed similar features to those of 1 except five 1H/13C resonances from C6 to C10, which indicated the structural difference between 1 and 2 to be in the double bond geometries. In fact, the composition of 14 carbon signals, the carbon connectivity, and the sites of functional groups in 2 proved to be completely the same as those in 1 by the interpretation of 13C, DEPT, COSY, and HMBC correlations (Figure 2). While an E configuration at C6 was evident from the coupling constant JH6,H7 = 15.6 Hz, JH8,H9 was unable to be read from the multiplicity pattern of H8 and H9 due to the intense second-order effects caused by a signal overlap of these resonances (δH 6.15 and 6.18, respectively). Although the E geometry at C8 was circumstantially obvious and supported by the deshielded allylic carbon atom C10 (δC 33.1 for 2 vs 28.3 for 1), a decisive evidence was acquired from spin system simulations using the software ‘nmrpeak’ [19], which gave the best match to the experimentally obtained 1H NMR spectrum with the setting of 3JH8,H9 = 15.6 Hz and 3JH7,H8 = 9.5 Hz (Figure 3). Thus, the C8 geometry was unambiguously determined to be E.

[1860-5397-16-29-3]

Figure 3: Spin system simulation for the C8–C9 double bond of 2.

α-Keto fatty acids are characterized by the presence of a keto group at the α-position of a carboxylic acid moiety. They are present in all living cells and play crucial roles in biological systems as they are involved in the Krebs cycle and glycolysis [20]. In contrast, keto fatty acids bearing a keto group in the middle of the carbon chain are relatively limited in their distribution in nature. Many of such natural keto fatty acids were found in plants, mainly as a constituent of seed oil [21-29]. Among them, rabdosia acids [30] and (10E,12E)-9-oxo-10,12-octadecadienoic acid [31] are the plant keto fatty acids containing the dienone moiety with trans,trans-configuration, but congeners with trans,cis-configuration have not been found in nature until the present work (Figure 4). Some of the keto fatty acids of plant origin were shown to exhibit pharmaceutically important activity. (9E,11E)-13-Oxooctadecadienoic acid is a PPARα activator found in tomato juice. This keto fatty acid decreases plasma and hepatic triglyceride in obese diabetic mice by activating PPARα transcription [32]. (10E,12E)-9-Oxooctadecadienoic acid isolated from eggplant calyx induces apoptosis in human ovarian cancer cells, leading to cell death [33]. One example of a keto fatty acid from the animal kingdom is (E)-9-oxo-2-decenoic acid, a sex pheromone found in royal jelly. Queen honey bees use this fatty acid to control the activity of worker bees [34]. (E)-7-Oxo-11,13-tetradecadienoic acid is another example of insect origin, identified from hair pencils of male Amauris butterflies (Amauris albimaculata), which is supposed to be a precursor material for the butterfly pheromone [35]. Furthermore, 4-oxo-2-alkenoic fatty acids were characterized as antimicrobial metabolites from an actinomycete [36] and a basidiomycete fungus [37]. In addition, long-chain saturated fatty acids possessing a keto group were detected in the solvent extract of Legionella by GC–MS analysis [38]. Fatty acid components in fresh water-derived Micrococcus species were comprehensively analyzed [39], but keto fatty acids like compounds 1 and 2, bearing a dienone system, are unprecedented as microbial metabolites.

[1860-5397-16-29-4]

Figure 4: Natural keto fatty acids of various origins.

Compounds 1 and 2 inhibited the growth of Tenacibaculum maritimum NBRC16015, a causative agent of skin infection of marine fish [40], and Rhizobium radiobacter NBRC14554, a causative agent of crown gall disease of plants [41]. The MIC values for 1 against T. maritimum and R. radiobacter were 50 and 6.2 µg/mL, respectively, while 2 was more potent against T. maritimum, with a MIC of 12.5 µg/mL, and less against R. radiobacter, with a MIC of 50 µg/mL, presenting an interesting contrast. No appreciable antimicrobial activity was observed for both compounds against bacterial strains of Micrococcus luteus ATCC9341, Staphylococcus aureus FDA209P JC-1, and Escherichia coli NIHJ JC-2 and yeast strains of Candida albicans NBRC0197 and Saccharomyces cerevisiae S100, nor cytotoxicity against murine leukemia P388 cells at 100 µM. Additionally, compounds 1 and 2 were evaluated for agonist activity to peroxisome proliferator-activated receptors (PPARs) because similar oxo fatty acids are known to act as PPAR agonists [42]. PPARs are ligand-activated transcription factors playing key roles in lipid and carbohydrate metabolism [43,44]. PPARα upregulates lipid uptake and β-oxidation of fatty acids, whereas PPARγ promotes adipocyte differentiation and adipokine production in adipose tissues to improve insulin sensitivity in diabetic patients [45-47]. Owing to these physiological functions in energy metabolism, PPARs are the molecular targets of metabolic disorders [48]. To assess the PPAR isoform specificity of 1 and 2, three reporter cell lines expressing luciferase genes in response to PPARα, PPARβ/δ, and PPARγ agonists were used [49]. The agonist activity was determined as a relative potency to the positive controls, WY14643 for PPARα, GW0742 for PPARβ/δ, and troglitazone for PPARγ. Both 1 and 2 induced activations of PPARα and PPARγ transcription but were not effective against PPARβ/δ (Figure 5). Compared to the activity at 12.5 μM, slight increases of PPARα and β/δ agonist activities were observed for 1 at the lower concentration of 6.25 μM, but the activity at 6.25 μM was almost equivalent to the activity level of the vehicle DMSO. We thus considered that 1 had no significant activity at 6.25 μM. Overall, 1 was lesser potent than 2, indicating that the geometry at C8 may play a crucial role in the binding to PPARs.

[1860-5397-16-29-5]

Figure 5: PPAR activation by 1 and 2.

Conclusion

In summary, UV-chemical screening of the coral-associated bacterium Micrococcus sp. C5-9 led to the discovery of two new unsaturated keto fatty acids, (6E,8Z)-5-oxo-6,8-tetradecadienoic acid (1) and its (6E,8E)-isomer 2. Compounds 1 and 2 showed selective antibacterial activity against the plant pathogen R. radiobacter and the fish pathogen T. maritimum, respectively. In addition, both 1 and 2 displayed agonistic activity against PPARα and PPARγ.

Experimental

General experimental procedure

UV and IR spectra were recorded on a Shimadzu UV-1800 and a Perkin-Elmer Spectrum 100 spectrophotometer, respectively. NMR spectra were obtained on a Bruker AVANCE 500 spectrometer in CDCl3 using the signals of the residual solvent (δH 7.26) and (δC 77.0) as internal standards. HRESIMS-TOF was recorded on a Bruker micrOTOF focus.

Microorganism

Strain C5-9 was collected from a stony coral, Catalaphyllia sp., obtained from an aquarium vendor in Osaka, Japan. A piece of the coral specimen (ca. 1 g) was surface-sterilized by washing with 70% ethanol, followed by rinsing with sterile natural seawater. The coral piece was homogenized by mortar and pestle with an equal volume of sterile natural seawater (1 mL), and the resulting suspension was serially diluted tenfold to 10−5. One-hundred μL aliquots of each dilution were spread onto Marine Agar 2216 (Difco), and the agar plates were cultivated at 23 °C for two days. Single colonies thus emerged on the plates, which were transferred onto a new agar medium to obtain pure isolates. One of these isolates, coded as C5-9, was identified as a member of the genus Micrococcus on the basis of 99.9% similarity in the 16S rRNA gene sequence (1395 nucleotides; DNA Data Bank of Japan/DDBJ accession number LC498624) to Micrococcus yunnanensis YIM 65004T (accession number FJ214355).

Fermentation

Strain C5-9 was maintained on Marine Agar 2216 (Difco). A loopful of strain C5-9 was inoculated into a 500 mL K-1 flask containing 100 mL of Marine Broth 2216 (Difco) as a seed culture. The seed culture was incubated at 30 °C on a rotary shaker at 200 rpm for two days. Three mL each of the seed culture were inoculated into 29 500 mL K-1 flasks containing 100 mL of A16 production medium, which consisted of glucose 2%, Pharmamedia (Traders Protein, Memphis, TN, USA) 1%, CaCO3 0.5%, Diaion HP-20 (Mitsubishi Chemical, Kanagawa, Japan) 1%, and natural seawater collected in Toyama Bay, Toyama, Japan. The pH value of the medium was adjusted to 7.0 before sterilization. The inoculated flasks were incubated at 30 °C for 5 days with rotational shaking using a rotary shaker at a speed of 200 rpm.

Extraction and isolation

After fermentation, 100 mL of 1-butanol were added to each flask, and the flasks were shaken for 1 h. The emulsified mixture was centrifuged at 6000 rpm for 10 min, and the organic layer was separated from the aqueous layer. The organic layer was concentrated in vacuo to afford 5.1 g of crude extract from 2.9 L of production culture. The extract was successively partitioned between 60% aqueous MeOH (500 mL) and CH2Cl2 (500 mL × 3) and the latter between 90% aqueous MeOH (250 mL) and n-hexane (250 mL × 3). The 90% aqueous MeOH layer was evaporated to dryness (577 mg) and then fractionated by ODS column chromatography with a gradient of MeCN–0.1% HCO2H in aqueous solution (2:8, 3:7, 4:6, 5:5, 6:4, 7:3, and 8:2, v/v). Fraction 5 (6:4) was concentrated in vacuo, and the remaining aqueous layer was extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated to give 27.5 mg of semipure material. Final purification was achieved by preparative HPLC (Cosmosil Cholester, Nacalai Tesque Inc., 10 × 250 mm, 4 mL/min, UV detection at 290 nm) with an isocratic elution of MeCN/0.1% HCO2H (63:37) to afford 1 (3.7 mg, tR 14.2 min) and 2 (2.4 mg, tR 15.7 min).

(6E,8Z)-5-Oxo-6,8-tetradecadienoic acid (1): pale yellow amorphous solid; UV (MeOH) λmax (log ε) 277 nm (4.25); IR (ATR) νmax: 3050, 2955, 1708, 1689 cm−1; HRESIMS-TOF (m/z): [M + Na]+ calcd for C14H22O3Na, 261.1461; found, 261.1453

(6E,8E)-5-Oxo-6,8-tetradecadienoic acid (2): pale yellow amorphous solid; UV (MeOH) λmax (log ε) 275 nm (4.30); IR (ATR) νmax: 3389, 2929, 1710, 1659 cm−1; HRESIMS-TOF (m/z): [M + Na]+ calcd for C14H22O3Na, 261.1461; found, 261.1458.

NMR spin system simulation

In order to determine the multiplicity pattern and the coupling constants for the double bond system of 2, spin system simulations were performed using the freeware nmrpeak.exe [19].

Antimicrobial assay

Antimicrobial assays were carried out in a similar manner as described in [18]. The antimicrobial activity was evaluated by the liquid microculture method using round-bottomed 96-well microtiter plates against five bacteria, Micrococcus luteus ATCC9341, Staphylococcus aureus FDA209P JC-1, Rhizobium radiobacter NBRC14554, Escherichia coli NIHJ JC-2, Tenacibaculum maritimum NBRC16015, and two yeasts, Candida albicans NBRC0197 and Saccharomyces cerevisiae S100, as indication strains. Mueller–Hinton Broth (Difco), Sabouraud Dextrose Broth (Difco), and Marine Broth (Difco) were used for bacteria, yeasts, and Tenacibaculum maritimum NBRC16015, respectively. Compounds 1 and 2, the reference drugs kanamycin sulfate for bacteria, sulfamethoxazole for R. radiobacter NBRC14554 and T. maritimum NBRC16015, and amphotericin B for yeasts, were made in twofold dilution series along the longer side of the plates by sequential transfer of 100 µL aliquots between the adjacent wells to which the same amount of medium was predispensed. To each well was added a 100 µL suspension of the indication strains prepared at ≈106 cfu/mL from a culture at the logarithmic growth phase. The solvent vehicle added to the top rows was set at 0.5% of the final culture volume to avoid the effect on the growth of microbes. The plates were incubated at 37 °C for 20 h for bacteria, at 24 °C for T. maritimum NBRC16015, and at 32 °C for yeasts. The tests were done in triplicates, and the absorbance at a wavelength of 650 nm was measured with the help of a microplate reader.

Cytotoxicity assay

The cytotoxicity assay was carried out in a similar manner as described in [17]. P388 murine leukemia cells were maintained in RPMI-1640 medium containing ʟ-glutamine (product no. 186-02155) supplemented with 10% fetal bovine serum and 0.1 mg/mL gentamicin sulfate. Compounds 1, 2, and doxorubicin as a reference were serially diluted by a factor of 3.16 (half-logarithmic dilution) in a 96-well round-bottom microtiter plate. To each well were seeded the cells at a final density of 5 × 103 cells/well, and 200 µL cultures thus made were incubated for 96 h at 37 °C in an atmosphere of 5% CO2 in air with 100% humidity. The viability of the cells was visualized by the addition of 50 μL of the medium containing XTT (1 mg/mL) and PMS (40 µg/mL) to each well. After incubating for 4 h at 37 °C, the medium was carefully removed by a suction aspirator, and formazan dye, formed by respiratory reduction by living cells, was quantified by the absorption at 450 nm, read by a microplate reader to calculate the rate of cell growth inhibition at each concentration, and the results of the triplicates were plotted on single-logarithmic charts to deduce the IC50 values.

PPAR activation assay

Measurements of PPARα, -β/δ, and -γ ligand activity was evaluated by a luciferase reporter gene assay system [49]. Briefly, COS-1 cells (5 × 105 cells) were transiently transfected with an expression plasmid containing the ligand-binding domain of human PPARα, -β/δ, and -γ fused to the GAL4 DNA-binding domain (pPPARα–GAL4, pPPARδ–GAL4, or pPPARγ–GAL4, 0.25 µg), a luciferase reporter plasmid 17m2G TATA Luc (p17m2G, 1 µg), and the pSEAP-control vector (1 µg, Clontech, CA, USA) by using the Effectene transfection reagent. Transfection was performed in 60 mm culture dishes according to the manufacturer’s instructions. After 16 h, the transfected cells were recovered and seeded into 96-well white multiwell plates, the indicated concentrations of the test compounds were added, and the plates were cultured for an additional 24 h at 37 °C in a 5% CO2 incubator. The luciferase activity and secreted alkaline phosphatase SEAP activity were measured in each well by using a Steady-Glo® luciferase assay (Promega, Madison, WI, USA) and Great ESCAPe SEAP Reporter System3 (Clontech), according to the manufacturer’s instructions. The SEAP activity level was used to correct the luciferase activity in each well. Each data value is presented as the mean ± standard error of three experiments.

Supporting Information

Supporting Information File 1: ESIMS-TOF, UV, IR, 1D, and 2D NMR spectra of 1 and 2.
Format: PDF Size: 1.7 MB Download

Acknowledgments

We thank Prof. Shigeaki Kato, University of Tokyo, for providing pPPARα–GAL4, pPPARδ–GAL4, pPPARγ–GAL4, and p17m2G. P388 cells were obtained from JCRB Cell Bank under the accession code JCRB0017 (Lot. 06252002).

Funding

This work was supported by JSPS KAKENHI Grant Number 24580156 to Y. I.

References

  1. Manivasagan, P.; Kang, K.-H.; Sivakumar, K.; Li-Chan, E. C. Y.; Oh, H.-M.; Kim, S.-K. Environ. Toxicol. Pharmacol. 2014, 38, 172–188. doi:10.1016/j.etap.2014.05.014
    Return to citation in text: [1]
  2. Manivasagan, P.; Venkatesan, J.; Sivakumar, K.; Kim, S.-K. Microbiol. Res. 2014, 169, 262–278. doi:10.1016/j.micres.2013.07.014
    Return to citation in text: [1] [2]
  3. Zotchev, S. B. J. Biotechnol. 2012, 158, 168–175. doi:10.1016/j.jbiotec.2011.06.002
    Return to citation in text: [1]
  4. Mahmoud, H. M.; Kalendar, A. A. Front. Microbiol. 2016, 7, No. 204. doi:10.3389/fmicb.2016.00204
    Return to citation in text: [1] [2]
  5. Brinkmann, C. M.; Marker, A.; Kurtböke, D. I. Diversity 2017, 9, No. 40. doi:10.3390/d9040040
    Return to citation in text: [1]
  6. Leal, M. C.; Calado, R.; Sheridan, C.; Alimonti, A.; Osinga, R. Trends Biotechnol. 2013, 31, 555–561. doi:10.1016/j.tibtech.2013.06.004
    Return to citation in text: [1]
  7. Fu, P.; Kong, F.; Wang, Y.; Wang, Y.; Liu, P.; Zuo, G.; Zhu, W. Chin. J. Chem. 2013, 31, 100–104. doi:10.1002/cjoc.201201062
    Return to citation in text: [1]
  8. Nong, X.-H.; Zhang, X.-Y.; Xu, X.-Y.; Wang, J.; Qi, S.-H. J. Nat. Prod. 2016, 79, 141–148. doi:10.1021/acs.jnatprod.5b00805
    Return to citation in text: [1]
  9. Nong, X.-H.; Wei, X.-Y.; Qi, S.-H. J. Antibiot. 2017, 70, 1047–1052. doi:10.1038/ja.2017.105
    Return to citation in text: [1]
  10. Chittpurna; Singh, P. K.; Verma, D.; Pinnaka, A. K.; Mayilraj, S.; Korpole, S. Int. J. Syst. Evol. Microbiol. 2011, 61, 2832–2836. doi:10.1099/ijs.0.028043-0
    Return to citation in text: [1]
  11. Prakash, O.; Nimonkar, Y.; Munot, H.; Sharma, A.; Vemuluri, V. R.; Chavadar, M. S.; Shouche, Y. S. Int. J. Syst. Evol. Microbiol. 2014, 64, 3427–3433. doi:10.1099/ijs.0.063339-0
    Return to citation in text: [1]
  12. Abdelmohsen, U. R.; Bayer, K.; Hentschel, U. Nat. Prod. Rep. 2014, 31, 381–399. doi:10.1039/c3np70111e
    Return to citation in text: [1]
  13. Bultel-Poncé, V.; Debitus, C.; Blond, A.; Cerceau, C.; Guyot, M. Tetrahedron Lett. 1997, 38, 5805–5808. doi:10.1016/s0040-4039(97)01283-5
    Return to citation in text: [1]
  14. Bultel-Poncé, V.; Berge, J.-P.; Debitus, C.; Nicolas, J.-L.; Guyot, M. Mar. Biotechnol. 1999, 1, 384–390. doi:10.1007/pl00011792
    Return to citation in text: [1] [2]
  15. Palomo, S.; González, I.; de la Cruz, M.; Martín, J.; Tormo, J. R.; Anderson, M.; Hill, R. T.; Vicente, F.; Reyes, F.; Genilloud, O. Mar. Drugs 2013, 11, 1071–1086. doi:10.3390/md11041071
    Return to citation in text: [1]
  16. Eltamany, E. E.; Abdelmohsen, U. R.; Ibrahim, A. K.; Hassanean, H. A.; Hentschel, U.; Ahmed, S. A. Bioorg. Med. Chem. Lett. 2014, 24, 4939–4942. doi:10.1016/j.bmcl.2014.09.040
    Return to citation in text: [1]
  17. Sharma, A. R.; Zhou, T.; Harunari, E.; Oku, N.; Trianto, A.; Igarashi, Y. J. Antibiot. 2019, 72, 634–639. doi:10.1038/s41429-019-0192-x
    Return to citation in text: [1] [2]
  18. Sharma, A. R.; Harunari, E.; Zhou, T.; Trianto, A.; Igarashi, Y. Beilstein J. Org. Chem. 2019, 15, 2327–2332. doi:10.3762/bjoc.15.225
    Return to citation in text: [1] [2]
  19. nmrpeak: http://ramonyan.ec-site.jp/nmr/index.html#PeakSim.
    Return to citation in text: [1] [2]
  20. Penteado, F.; Lopes, E. F.; Alves, D.; Perin, G.; Jacob, R. G.; Lenardão, E. J. Chem. Rev. 2019, 119, 7113–7278. doi:10.1021/acs.chemrev.8b00782
    Return to citation in text: [1]
  21. Bagby, M. O.; Smith, C. R., Jr.; Wolff, I. A. Lipids 1966, 1, 263–267. doi:10.1007/bf02531613
    Return to citation in text: [1]
  22. Phillips, B. E.; Smith, C. R., Jr.; Tjarks, L. W. Biochim. Biophys. Acta, Lipids Lipid Metab. 1970, 210, 353–359. doi:10.1016/0005-2760(70)90031-7
    Return to citation in text: [1]
  23. Mahmood, C.; Daulatabad, J. D.; Mulla, G. M. M.; Mirajkar, A. M.; Hosamani, K. M. Phytochemistry 1991, 30, 2399–2400. doi:10.1016/0031-9422(91)83659-9
    Return to citation in text: [1]
  24. Jamal, S.; Ahmad, I.; Agarwal, R.; Ahmad, M.; Osman, S. M. Phytochemistry 1987, 26, 3067–3069. doi:10.1016/s0031-9422(00)84595-1
    Return to citation in text: [1]
  25. Daulatabad, C. D.; Bhat, G. G.; Jamkhandi, A. M. Phytochemistry 1996, 42, 889–890. doi:10.1016/0031-9422(95)00961-2
    Return to citation in text: [1]
  26. Daulatabad, C. D.; Mulla, G. M.; Mirajkar, A. M.; Hosamani, K. M. J. Am. Oil Chem. Soc. 1992, 69, 188–189. doi:10.1007/bf02540574
    Return to citation in text: [1]
  27. Gunstone, F. D.; Subbarao, R. Chem. Phys. Lipids 1967, 1, 349–359. doi:10.1016/0009-3084(67)90012-6
    Return to citation in text: [1]
  28. Hosamani, K. M. Ind. Eng. Chem. Res. 1996, 35, 326–331. doi:10.1021/ie940557l
    Return to citation in text: [1]
  29. Brown, W. B.; Farmer, E. H. Biochem. J. 1935, 29, 631–639. doi:10.1042/bj0290631
    Return to citation in text: [1]
  30. Zhao, C.; Xing, G.-S.; Xu, R.; Jin, D.-J.; Duan, H.-Q.; Xu, W.-G.; Tang, S.-A. Chem. Nat. Compd. 2016, 52, 205–207. doi:10.1007/s10600-016-1595-6
    Return to citation in text: [1]
  31. Binder, R. G.; Applewhite, T. H.; Diamond, M. J.; Goldblatt, L. A. J. Am. Oil Chem. Soc. 1964, 41, 108–111. doi:10.1007/bf02673484
    Return to citation in text: [1]
  32. Kim, Y.-i.; Hirai, S.; Goto, T.; Ohyane, C.; Takahashi, H.; Tsugane, T.; Konishi, C.; Fujii, T.; Inai, S.; Iijima, Y.; Aoki, K.; Shibata, D.; Takahashi, N.; Kawada, T. PLoS One 2012, 7, e31317. doi:10.1371/journal.pone.0031317
    Return to citation in text: [1]
  33. Zhao, B.; Tomoda, Y.; Mizukami, H.; Makino, T. J. Nat. Med. 2015, 69, 296–302. doi:10.1007/s11418-015-0892-x
    Return to citation in text: [1]
  34. Cromer, D. T.; Larson, A. C. Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem. 1972, 28, 2128–2132. doi:10.1107/s0567740872005655
    Return to citation in text: [1]
  35. Schulz, S.; Francke, W.; Boppré, M. Biol. Chem. Hoppe-Seyler 1988, 369, 633–638. doi:10.1515/bchm3.1988.369.2.633
    Return to citation in text: [1]
  36. Pfefferle, C.; Kempter, C.; Metzger, J. W.; Fiedler, H.-P. J. Antibiot. 1996, 49, 826–828. doi:10.7164/antibiotics.49.826
    Return to citation in text: [1]
  37. Teichert, A.; Lubken, T.; Schmidt, J.; Porzel, A.; Arnold, N.; Wessjohann, L. Z. Naturforsch., B: J. Chem. Sci. 2005, 60, 25–32. doi:10.1515/znb-2005-0105
    Return to citation in text: [1]
  38. Moll, H.; Sonesson, A.; Jantzen, E.; Marre, R.; Zähringer, U. FEMS Microbiol. Lett. 1992, 97, 1–6. doi:10.1111/j.1574-6968.1992.tb05430.x
    Return to citation in text: [1]
  39. Carballeira, N. M.; Pagán, M.; Shalabi, F.; Nechev, J. T.; Lahtchev, K.; Ivanova, A.; Stefanov, K. J. Nat. Prod. 2000, 63, 1573–1575. doi:10.1021/np000305r
    Return to citation in text: [1]
  40. Faílde, L. D.; Losada, A. P.; Bermúdez, R.; Santos, Y.; Quiroga, M. I. Microb. Pathog. 2013, 65, 82–88. doi:10.1016/j.micpath.2013.09.003
    Return to citation in text: [1]
  41. Gelvin, S. B. Plant Physiol. 1990, 92, 281–285. doi:10.1104/pp.92.2.281
    Return to citation in text: [1]
  42. Moldes-Anaya, A.; Sæther, T.; Uhlig, S.; Nebb, H. I.; Larsen, T.; Eilertsen, H. C.; Paulsen, S. M. Mar. Drugs 2017, 15, No. 148. doi:10.3390/md15060148
    Return to citation in text: [1]
  43. Wang, Y.-X. Cell Res. 2010, 20, 124–137. doi:10.1038/cr.2010.13
    Return to citation in text: [1]
  44. Hong, F.; Pan, S.; Guo, Y.; Xu, P.; Zhai, Y. Molecules 2019, 24, No. 2545. doi:10.3390/molecules24142545
    Return to citation in text: [1]
  45. Pawlak, M.; Lefebvre, P.; Staels, B. J. Hepatol. 2015, 62, 720–733. doi:10.1016/j.jhep.2014.10.039
    Return to citation in text: [1]
  46. Mirzaei, K.; Hossein-nezhad, A.; Keshavarz, S. A.; Koohdani, F.; Saboor-Yaraghi, A. A.; Hosseini, S.; Eshraghian, M. R.; Djalali, M. Diabetol. Metab. Syndr. 2013, 5, 79. doi:10.1186/1758-5996-5-79
    Return to citation in text: [1]
  47. Picard, F.; Auwerx, J. Annu. Rev. Nutr. 2002, 22, 167–197. doi:10.1146/annurev.nutr.22.010402.102808
    Return to citation in text: [1]
  48. Han, L.; Shen, W.-J.; Bittner, S.; Kraemer, F. B.; Azhar, S. Future Cardiol. 2017, 13, 279–296. doi:10.2217/fca-2017-0019
    Return to citation in text: [1]
  49. Matsuura, N.; Gamo, K.; Miyachi, H.; Iinuma, M.; Kawada, T.; Takahashi, N.; Akao, Y.; Tosa, H. Biosci., Biotechnol., Biochem. 2013, 77, 2430–2435. doi:10.1271/bbb.130541
    Return to citation in text: [1] [2]

Interesting articles

Constantinos G. Neochoritis, Maryam Kazemi Miraki, Eman M. M. Abdelraheem, Ewa Surmiak, Tryfon Zarganes-Tzitzikas, Beata Łabuzek, Tad A. Holak and Alexander Dömling

© 2020 Sharma et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (https://www.beilstein-journals.org/bjoc)

 
Back to Article List